On the recordJuly 27, 2011
If we don't have measurement tools to determine whether a fee system produces a better outcome, then I'm not sure why we would sign off on it as policymakers.
Source
congress.govIf we don't have measurement tools to determine whether a fee system produces a better outcome, then I'm not sure why we would sign off on it as policymakers.
Burr questions the lack of metrics for evaluating FDA fee agreements.
Share
More from Richard Burr
When is somebody going to share with the American people the destination we are trying to get to and how we are going to get to that destination?
in a few minutes, I am going to ask unanimous consent for the passage of the bill. In the interim, I would like to yield some time to my good friend Senator Wicker. The PRESIDING OFFICER. The Senator from Mississippi.
I will work with you as aggressively as I can to get the answers to the questions that are unanswered today on infant formula.